These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34452051)

  • 21. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.
    Chodick G; Tene L; Patalon T; Gazit S; Ben Tov A; Cohen D; Muhsen K
    JAMA Netw Open; 2021 Jun; 4(6):e2115985. PubMed ID: 34097044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart.
    Modenese A; Paduano S; Bargellini A; Bellucci R; Marchetti S; Bruno F; Grazioli P; Vivoli R; Gobba F
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34203652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interim Estimates of COVID-19 Vaccine Effectiveness in a Mass Vaccination Setting: Data from an Italian Province.
    Flacco ME; Soldato G; Acuti Martellucci C; Carota R; Di Luzio R; Caponetti A; Manzoli L
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34200538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study.
    Pottegård A; Lund LC; Karlstad Ø; Dahl J; Andersen M; Hallas J; Lidegaard Ø; Tapia G; Gulseth HL; Ruiz PL; Watle SV; Mikkelsen AP; Pedersen L; Sørensen HT; Thomsen RW; Hviid A
    BMJ; 2021 May; 373():n1114. PubMed ID: 33952445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic Adverse Events and Use of Antipyretics Predict the Neutralizing Antibody Positivity Early after the First Dose of ChAdOx1 Coronavirus Disease Vaccine.
    Park JY; Choi SH; Chung JW; Hwang MH; Kim MC
    J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34199053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021.
    Konu YR; Gbeasor-Komlanvi FA; Yerima M; Sadio AJ; Tchankoni MK; Zida-Compaore WIC; Nayo-Apetsianyi J; Afanvi KA; Agoro S; Salou M; Landoh DE; Nyansa AB; Boko E; Mijiyawa M; Ekouevi DK
    Arch Public Health; 2021 Nov; 79(1):207. PubMed ID: 34819146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection.
    Morales-Núñez JJ; Muñoz-Valle JF; Meza-López C; Wang LF; Machado Sulbarán AC; Torres-Hernández PC; Bedolla-Barajas M; De la O-Gómez B; Balcázar-Félix P; Hernández-Bello J
    Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
    De Coster I; Leroux-Roels I; Bandyopadhyay AS; Gast C; Withanage K; Steenackers K; De Smedt P; Aerssens A; Leroux-Roels G; Oberste MS; Konopka-Anstadt JL; Weldon WC; Fix A; Konz J; Wahid R; Modlin J; Clemens R; Costa Clemens SA; Bachtiar NS; Van Damme P
    Lancet; 2021 Jan; 397(10268):39-50. PubMed ID: 33308429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
    Folegatti PM; Bittaye M; Flaxman A; Lopez FR; Bellamy D; Kupke A; Mair C; Makinson R; Sheridan J; Rohde C; Halwe S; Jeong Y; Park YS; Kim JO; Song M; Boyd A; Tran N; Silman D; Poulton I; Datoo M; Marshall J; Themistocleous Y; Lawrie A; Roberts R; Berrie E; Becker S; Lambe T; Hill A; Ewer K; Gilbert S
    Lancet Infect Dis; 2020 Jul; 20(7):816-826. PubMed ID: 32325038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study.
    Salmerón Ríos S; Mas Romero M; Cortés Zamora EB; Tabernero Sahuquillo MT; Romero Rizos L; Sánchez-Jurado PM; Sánchez-Nievas G; Señalada JJB; García Nogueras I; Estrella Cazalla JD; Andrés-Pretel F; Murillo Romero A; Lauschke VM; Stebbing J; Abizanda P
    J Am Geriatr Soc; 2021 Jun; 69(6):1441-1447. PubMed ID: 33768521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project.
    Polewska K; Tylicki P; Biedunkiewicz B; Rucińska A; Szydłowska A; Kubanek A; Rosenberg I; Rodak S; Ślizień W; Renke M; Dębska-Ślizień A; Tylicki L
    Medicina (Kaunas); 2021 Jul; 57(7):. PubMed ID: 34357013
    [No Abstract]   [Full Text] [Related]  

  • 32. BNT162b2 mRNA Vaccine Interference with Co-Administration of Tdap Vaccine.
    Chilimuri S; Mantri N; Shrestha E; Sun H; Gongati S; Zahid M; Kelly P
    Am J Case Rep; 2021 Jul; 22():e933003. PubMed ID: 34304240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2.
    Lee SW; Lee H; Lee SK; Moon JY; Moon S; Chung SJ; Yeo Y; Park TS; Won Park D; Kim TH; Sohn JW; Yoon HJ; Kim SH
    Front Med (Lausanne); 2021; 8():738049. PubMed ID: 34660644
    [No Abstract]   [Full Text] [Related]  

  • 34. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [
    Cohen D; Krauthammer SH; Wolf I; Even-Sapir E
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1854-1863. PubMed ID: 33774684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects.
    Fabricius D; Ludwig C; Scholz J; Rode I; Tsamadou C; Jacobsen EM; Winkelmann M; Grempels A; Lotfi R; Janda A; Körper S; Adler G; Debatin KM; Schrezenmeier H; Jahrsdörfer B
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adenovirus and RNA-based COVID-19 vaccines' perceptions and acceptance among healthcare workers in Saudi Arabia: a national survey.
    Temsah MH; Barry M; Aljamaan F; Alhuzaimi A; Al-Eyadhy A; Saddik B; Alrabiaah A; Alsohime F; Alhaboob A; Alhasan K; Alaraj A; Halwani R; Alamro NM; Al-Shahrani FS; Jamal A; Alsubaie S; Memish ZA; Al-Tawfiq JA
    BMJ Open; 2021 Jun; 11(6):e048586. PubMed ID: 34155080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers.
    Coppeta L; Balbi O; Grattagliano Z; Mina GG; Pietroiusti A; Magrini A; Bolcato M; Trabucco Aurilio M
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34204252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergency Department Utilization by In-hospital Healthcare Workers after COVID-19 Vaccination.
    Park MJ; Choi YJ; Choi S
    J Korean Med Sci; 2021 Jul; 36(27):e196. PubMed ID: 34254475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination.
    Puro V; Castilletti C; Agrati C; Goletti D; Leone S; Agresta A; Cimini E; Tartaglia E; Casetti R; Colavita F; Meschi S; Matusali G; Lapa D; Najafi Fard S; Aiello A; Farrone C; Gallì P; Capobianchi MR; Ippolito G; On Behalf Of The Inmi Covid-Vaccine Study Group
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34201065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survey of Adverse Events After The First Dose of The ChAdOx1 nCoV-19 Vaccine: A Single-Center Experience in Korea.
    Song JE; Oh GB; Park HK; Lee SS; Kwak YG
    Infect Chemother; 2021 Sep; 53(3):557-561. PubMed ID: 34405593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.